Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Individualisation of antiviral therapy for chronic hepatitis C.

Journal of gastroenterology and hepatology - 1 Jul 2010

Teoh Narci C, Farrell Geoffrey C, Chan Henry L-Y

Abstract excerpt

The combination of pegylated-interferon (PEG-IFN)/ribavirin is currently the standard of care antiviral treatment for chronic hepatitis C (CHC), but optimal results require an individual approach. Key issues are to deliver doses that confer optimal antiviral efficacy against hepatitis C virus (HCV) for a time sufficient to minimise relapse. Viral monitoring during therapy guides the subsequent treatment course,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ribavirin
Share to Drug Administration Schedule
Share to Drug Monitoring

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Hepatitis C, Chronic

Share to Interferons

Share to Patient Care Team

Share to Precision Medicine

Source

Identifiers

PMID: 20594246
DOI: 10.1111/j.1440-1746.2010.06392.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Individualisation of antiviral therapy for chronic hepatitis C.PMID 20594246Read ↗

Individualization of antiviral treatment regimens for chronic hepatitis C.Semantic proximity Read ↗

Customizing treatment to patient populations.Semantic proximity Read ↗

Treatment optimisation for hepatitis C in the era of combination direct-acting antiviral therapy: a systematic review and meta-analysisSemantic proximity Read ↗

Tailoring the length of antiviral treatment for hepatitis C.Semantic proximity Read ↗

Expert opinion on the treatment of patients with chronic hepatitis C.Semantic proximity Read ↗

How to optimize HCV therapy in genotype 2 patients.Semantic proximity Read ↗

Initial treatment for chronic hepatitis C: current therapies and their optimal dosing and duration.Semantic proximity Read ↗

Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3.Semantic proximity Read ↗

Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks.Semantic proximity Read ↗

Hepatitis C treatment: shorter and better?Semantic proximity Read ↗

Optimizing treatment regimens in hepatitis C.Semantic proximity Read ↗

Optimal dose of peginterferon and ribavirin for treatment of chronic hepatitis C.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.